Gilead Sciences (GILD), Arcus Biosciences (RCUS) Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/8/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. SPY
6. RIVN
7. NVDA
8. LMT
9. WMT
10. CMPS

Go back to Gilead Sciences (GILD), Arcus Biosciences (RCUS) Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

May 27, 2020 7:11 AM EDT

Arcus to Receive $175 Million Upfront Payment and $200 Million Equity Investment and up to $1.6 Billion Plus in Potential R&D Funding, Opt-in and Milestone Payments with Respect to its Current Clinical Product Candidates

Gilead Gains Broad Access to Arcuss Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways

Companies to Co-commercialize Gilead-Optioned Programs in the U.S. with Equal Profit Share; Arcus to Receive Double-Digit Royalties Outside the U.S.

Arcus to Continue to Independently... More